Cellectis S.A. (CLLS) NASDAQ

Currency In USD

Key Executives

Name	Title	Pay	Year Born
David J. Sourdive	Co-Founder, Deputy Chief Executive Officer, Executive Vice President of CMC & Manufacturing and Director	636,274	1967
Andre Choulika	Co-Founder, Chief Executive Officer & Director	982,873	1965
Jean Charles Epinat	Chief Technological Officer	0	N/A
Stephan Reynier	Chief Regulatory & Pharmaceutical Compliance Officer	0	1969
Kyung Nam-Wortman	Executive Vice President & Chief Human Resources Officer	0	1970
Marie-Bleuenn Terrier	General Counsel & Secretary of the Board of Directors	0	1982
Pascalyne Wilson	Director of Communications	0	N/A
Valerie Cros	Principal Financial Officer & Principal Accounting Officer	0	N/A
Philippe Duchateau	Chief Scientific Officer	0	1963
Arthur Stril	Chief Financial Officer & Chief Business Officer	0	1989

Name

Title

Pay

Year Born

David J. Sourdive

Co-Founder, Deputy Chief Executive Officer, Executive Vice President of CMC & Manufacturing and Director

636,274

1967

Andre Choulika

Co-Founder, Chief Executive Officer & Director

982,873

1965

Jean Charles Epinat

Chief Technological Officer

N/A

Stephan Reynier

Chief Regulatory & Pharmaceutical Compliance Officer

1969

Kyung Nam-Wortman

Executive Vice President & Chief Human Resources Officer

1970

Marie-Bleuenn Terrier

General Counsel & Secretary of the Board of Directors

1982

Pascalyne Wilson

Director of Communications

N/A

Valerie Cros

Principal Financial Officer & Principal Accounting Officer

N/A

Philippe Duchateau

Chief Scientific Officer

1963

Arthur Stril

Chief Financial Officer & Chief Business Officer

1989

Description

Cellectis S.A. is a biotechnology firm in the clinical development stage, concentrating on the creation of immuno-oncology therapies. These therapies harness gene-edited T-cells engineered to express chimeric antigen receptors, designed to specifically identify and eliminate malignant cells. Its operations are divided into two distinct divisions: Therapeutics and Plants. The therapeutic pipeline includes several product candidates currently undergoing development. Among these is UCART19, an allogeneic T-cell therapy targeting CD19-expressing blood cancers such as acute lymphoblastic leukemia. Other key developments encompass ALLO-501 and ALLO-501A, designed for diffuse large B-cell lymphoma and follicular lymphoma in relapsed or refractory patients; ALLO-316, intended for Renal Cell Carcinoma; UCART123 for acute myeloid leukemia; and UCART22 for B-cell acute lymphoblastic leukemia. Furthermore, UCARTCS1 and ALLO-715 are being developed to combat multiple myeloma. Strategic partnerships form a crucial part of its operations, encompassing alliances with entities such as Allogene Therapeutics, Inc., Les Laboratoires Servier, The University of Texas M.D. Anderson Cancer Center, and Iovance Biotherapeutics. The firm also maintains a dedicated research and development collaboration with Cytovia Therapeutics, Inc. Established in 1999, Cellectis S.A. maintains its principal offices in Paris, France.